Serum angiogenin levels predict treatment response in patients with stage IV melanoma

P. Vihinen, M. Kallioinen, M.S. Vuoristo, Johanna Ivaska, K.J. Syrjänen, M. Hahka-Kemppinen, P.L. Kellokumpu-Lehtinen, S.O. Pyrhönen

Research output: Contribution to journalArticleScientificpeer-review

14 Citations (Scopus)

Abstract

This work was conducted to find out new potential serum markers and study their role as predictive factors in patients with metastatic melanoma. Serum samples from 68 patients with stage IV malignant melanoma were collected just before current treatment and screened for 79 different cytokines by using a multi-cytokine array. Angiogenin, which is a protein capable of promoting angiogenesis, was found to be markedly elevated among a sub-group of patients with progressive disease (PD) and thus was subjected to further analysis. The mean serum angiogenin level was 270 ng/ml and the median 236 ng/ml (STD 163 ng/ml). Concentrations were significantly higher among men than in women (P = 0.031), whereas patient’s age, site of the primary tumour, Clark’s or Breslow’s classifications were not associated with angiogenin levels. Patients with only lymph node metastases had markedly lower angiogenin levels than those with metastases at other sites (P = 0.05). High angiogenin levels were significantly (P = 0.015; Kruskal–Wallis) associated with poor treatment response with chemoimmunotherapy. Treatment-related survival (TRS) was shorter (10 months) in patients with above-median values than in those with below-median levels (19 months, P = NS). Cox multivariate regression model was used to control for the confounding by the classical prognostic factors of melanoma (age, sex, disease burden, performance score, site of metastases). Disease burden was the only variable that remained in the model as a significant independent predictor of TRS (P = 0.044). These data suggest that serum angiogenin levels might be of predictive value in the evaluation of treatment response for patients with stage IV melanoma.
Original languageEnglish
Pages (from-to)567-574
JournalClinical and Experimental Metastasis
Volume24
Issue number7
DOIs
Publication statusPublished - 2007
MoE publication typeA1 Journal article-refereed

Fingerprint

Melanoma
Serum
Neoplasm Metastasis
Therapeutics
Cytokines
Survival
Sexually Transmitted Diseases
angiogenin
Biomarkers
Lymph Nodes
Neoplasms
Proteins

Keywords

  • Angiogenin
  • Cytokine array
  • Melanoma
  • Prognosis
  • Survival

Cite this

Vihinen, P., Kallioinen, M., Vuoristo, M. S., Ivaska, J., Syrjänen, K. J., Hahka-Kemppinen, M., ... Pyrhönen, S. O. (2007). Serum angiogenin levels predict treatment response in patients with stage IV melanoma. Clinical and Experimental Metastasis, 24(7), 567-574. https://doi.org/10.1007/s10585-007-9093-7
Vihinen, P. ; Kallioinen, M. ; Vuoristo, M.S. ; Ivaska, Johanna ; Syrjänen, K.J. ; Hahka-Kemppinen, M. ; Kellokumpu-Lehtinen, P.L. ; Pyrhönen, S.O. / Serum angiogenin levels predict treatment response in patients with stage IV melanoma. In: Clinical and Experimental Metastasis. 2007 ; Vol. 24, No. 7. pp. 567-574.
@article{f1dcb9ae65d5416babd54cb29c92dab2,
title = "Serum angiogenin levels predict treatment response in patients with stage IV melanoma",
abstract = "This work was conducted to find out new potential serum markers and study their role as predictive factors in patients with metastatic melanoma. Serum samples from 68 patients with stage IV malignant melanoma were collected just before current treatment and screened for 79 different cytokines by using a multi-cytokine array. Angiogenin, which is a protein capable of promoting angiogenesis, was found to be markedly elevated among a sub-group of patients with progressive disease (PD) and thus was subjected to further analysis. The mean serum angiogenin level was 270 ng/ml and the median 236 ng/ml (STD 163 ng/ml). Concentrations were significantly higher among men than in women (P = 0.031), whereas patient’s age, site of the primary tumour, Clark’s or Breslow’s classifications were not associated with angiogenin levels. Patients with only lymph node metastases had markedly lower angiogenin levels than those with metastases at other sites (P = 0.05). High angiogenin levels were significantly (P = 0.015; Kruskal–Wallis) associated with poor treatment response with chemoimmunotherapy. Treatment-related survival (TRS) was shorter (10 months) in patients with above-median values than in those with below-median levels (19 months, P = NS). Cox multivariate regression model was used to control for the confounding by the classical prognostic factors of melanoma (age, sex, disease burden, performance score, site of metastases). Disease burden was the only variable that remained in the model as a significant independent predictor of TRS (P = 0.044). These data suggest that serum angiogenin levels might be of predictive value in the evaluation of treatment response for patients with stage IV melanoma.",
keywords = "Angiogenin, Cytokine array, Melanoma, Prognosis, Survival",
author = "P. Vihinen and M. Kallioinen and M.S. Vuoristo and Johanna Ivaska and K.J. Syrj{\"a}nen and M. Hahka-Kemppinen and P.L. Kellokumpu-Lehtinen and S.O. Pyrh{\"o}nen",
year = "2007",
doi = "10.1007/s10585-007-9093-7",
language = "English",
volume = "24",
pages = "567--574",
journal = "Clinical and Experimental Metastasis",
issn = "0262-0898",
publisher = "Springer",
number = "7",

}

Vihinen, P, Kallioinen, M, Vuoristo, MS, Ivaska, J, Syrjänen, KJ, Hahka-Kemppinen, M, Kellokumpu-Lehtinen, PL & Pyrhönen, SO 2007, 'Serum angiogenin levels predict treatment response in patients with stage IV melanoma', Clinical and Experimental Metastasis, vol. 24, no. 7, pp. 567-574. https://doi.org/10.1007/s10585-007-9093-7

Serum angiogenin levels predict treatment response in patients with stage IV melanoma. / Vihinen, P.; Kallioinen, M.; Vuoristo, M.S.; Ivaska, Johanna; Syrjänen, K.J.; Hahka-Kemppinen, M.; Kellokumpu-Lehtinen, P.L.; Pyrhönen, S.O.

In: Clinical and Experimental Metastasis, Vol. 24, No. 7, 2007, p. 567-574.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Serum angiogenin levels predict treatment response in patients with stage IV melanoma

AU - Vihinen, P.

AU - Kallioinen, M.

AU - Vuoristo, M.S.

AU - Ivaska, Johanna

AU - Syrjänen, K.J.

AU - Hahka-Kemppinen, M.

AU - Kellokumpu-Lehtinen, P.L.

AU - Pyrhönen, S.O.

PY - 2007

Y1 - 2007

N2 - This work was conducted to find out new potential serum markers and study their role as predictive factors in patients with metastatic melanoma. Serum samples from 68 patients with stage IV malignant melanoma were collected just before current treatment and screened for 79 different cytokines by using a multi-cytokine array. Angiogenin, which is a protein capable of promoting angiogenesis, was found to be markedly elevated among a sub-group of patients with progressive disease (PD) and thus was subjected to further analysis. The mean serum angiogenin level was 270 ng/ml and the median 236 ng/ml (STD 163 ng/ml). Concentrations were significantly higher among men than in women (P = 0.031), whereas patient’s age, site of the primary tumour, Clark’s or Breslow’s classifications were not associated with angiogenin levels. Patients with only lymph node metastases had markedly lower angiogenin levels than those with metastases at other sites (P = 0.05). High angiogenin levels were significantly (P = 0.015; Kruskal–Wallis) associated with poor treatment response with chemoimmunotherapy. Treatment-related survival (TRS) was shorter (10 months) in patients with above-median values than in those with below-median levels (19 months, P = NS). Cox multivariate regression model was used to control for the confounding by the classical prognostic factors of melanoma (age, sex, disease burden, performance score, site of metastases). Disease burden was the only variable that remained in the model as a significant independent predictor of TRS (P = 0.044). These data suggest that serum angiogenin levels might be of predictive value in the evaluation of treatment response for patients with stage IV melanoma.

AB - This work was conducted to find out new potential serum markers and study their role as predictive factors in patients with metastatic melanoma. Serum samples from 68 patients with stage IV malignant melanoma were collected just before current treatment and screened for 79 different cytokines by using a multi-cytokine array. Angiogenin, which is a protein capable of promoting angiogenesis, was found to be markedly elevated among a sub-group of patients with progressive disease (PD) and thus was subjected to further analysis. The mean serum angiogenin level was 270 ng/ml and the median 236 ng/ml (STD 163 ng/ml). Concentrations were significantly higher among men than in women (P = 0.031), whereas patient’s age, site of the primary tumour, Clark’s or Breslow’s classifications were not associated with angiogenin levels. Patients with only lymph node metastases had markedly lower angiogenin levels than those with metastases at other sites (P = 0.05). High angiogenin levels were significantly (P = 0.015; Kruskal–Wallis) associated with poor treatment response with chemoimmunotherapy. Treatment-related survival (TRS) was shorter (10 months) in patients with above-median values than in those with below-median levels (19 months, P = NS). Cox multivariate regression model was used to control for the confounding by the classical prognostic factors of melanoma (age, sex, disease burden, performance score, site of metastases). Disease burden was the only variable that remained in the model as a significant independent predictor of TRS (P = 0.044). These data suggest that serum angiogenin levels might be of predictive value in the evaluation of treatment response for patients with stage IV melanoma.

KW - Angiogenin

KW - Cytokine array

KW - Melanoma

KW - Prognosis

KW - Survival

U2 - 10.1007/s10585-007-9093-7

DO - 10.1007/s10585-007-9093-7

M3 - Article

VL - 24

SP - 567

EP - 574

JO - Clinical and Experimental Metastasis

JF - Clinical and Experimental Metastasis

SN - 0262-0898

IS - 7

ER -

Vihinen P, Kallioinen M, Vuoristo MS, Ivaska J, Syrjänen KJ, Hahka-Kemppinen M et al. Serum angiogenin levels predict treatment response in patients with stage IV melanoma. Clinical and Experimental Metastasis. 2007;24(7):567-574. https://doi.org/10.1007/s10585-007-9093-7